Araştırma Makalesi
BibTex RIS Kaynak Göster

Psödoeksfoliasyon ve aköz hümörde matriks metalloproteinaz-2 düzeyi

Yıl 2019, Cilt: 44 Sayı: 3, 835 - 839, 30.09.2019
https://doi.org/10.17826/cumj.507221

Öz

Amaç: Bu çalışmanın amacı primer açık açılı glokom (PAAG), psödoeksfoliasyon sendromu (PES), psödoeksfoliatif glokom (PEG) hastalarında aköz hümörde matriks metalloproteinaz-2 (MMP-2) düzeylerini araştırmaktır.

Gereç ve Yöntem: Bu prospektif çalışmada PES, PEG, PAAG' lu olgular ile kontrol grubunda yer alan kataraktlı olgularla birlikte toplam 97 hastanın 117 gözünden alınan humör aköz örneklerinde MMP-2 düzeyleri immünoassay ELİSA yöntemi ile ölçüldü. Her grup kontrol grubu ve birbirleri ile karşılaştırıldı.

Bulgular: Humörde aközde tespit edilen total MMP-2 seviyeleri; kontrol grubunda ortalama 56.69±51.3 ng/ml, PES grubunda 97.84±81.12 ng/ml, PEG grubunda 108.00±83.7 ng/ml ve PAAG grubunda 83.89±71.68 ng/ml idi. PES, PEG ve PAAG grubunda bulunan MMP-2 seviyeleri, kontrol grubu ile karşılaştırıldığında yüksek bulunmasına rağmen PES, PEG ve PAAG grupları arasında humör aköz ortalama MMP-2 düzeylerinde istatistiksel olarak anlamlı fark yoktu.

Sonuç: Çalışmamızda PE gruplarında, hem kontrol grubu hem de PAAG’lu gruba göre ortalama MMP-2 seviyelerinin yüksek olduğu bulundu. Ancak PE’lu grup ile PAAG grubu arasında istatistiksel anlamlı bir fark yoktu. 

Sonuç olarak PE’lu olgularda MMP-2 döngüsündeki bozukluğun PEM birikiminde önemli mekanizmalardan biri olabileceği ve GİB artışında da önemli rol oynadığı kanısına varıldı.  


Kaynakça

  • 1. Schlötzer-Schrehardt U, Naumann GOH. Morphology of exfoliation syndrome. In Exfoliation Syndrome and Exfoliative Glaucoma. ((Eds G Holló, AG Konstas):35-42. Savona, Italy, European Glaucoma Society, 2012.
  • 2. Schweitzer C. Pseudoexfoliation syndrome and pseudoexfoliation glaucoma. J Fr Ophthalmol. 2018;41:78-90.
  • 3. Gartaganis SP, Georgakopoulos CD, Mela EK. Matrix metalloproteinases and their inhibitors in exfoliation syndrome. Ophthalmic Res. 2002;34:165-71.
  • 4. Ritch R, Schöltzer-Schrehardt U. Exfoliation syndrome. Survey Ophthalmol. 2001;45:265-315.
  • 5. Garweg JG, Zandi S, Pfister IB, Skowronska M, Gerhardt C. Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma. PLoS One. 2017;12:e0182571.
  • 6. Grzybowski A, Kanclerz P, Ritch R. The history of exfoliation syndrome. Asia Pac J Ophthalmol (Phila). 2019;8:55-61.
  • 7. Clark AF. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci. 1998;39:2514–6.
  • 8. Van Buskirk EM, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol. 1992;113:447-52.
  • 9. Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117–25.
  • 10. Määttä M, Tervahartiala T, Harju M, Airaksinen J, Autio-Harmainen H, Sorsa T. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. J Glaucoma. 2005;14:64–9.
  • 11. Bradley JM, Vranka J, Colvis CM, Conger DM, Alexander JP, Fisk AS et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649–58.
  • 12. Ando H, Twining SS, Yue BY JT. MMPs and proteinase inhibitors in the human aqueous humor. Invest Ophthalmol Vis Sci. 1993;34:3541-8.
  • 13. Woessner JF Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci. 1994;732:11–21.
  • 14. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–4.
  • 15. Kee C, Son S, Ahn BH. The relationship between gelatinase A activity in aqueous humor and glaucoma. J Glaucoma 1999;8:51-5.
  • 16. Digirolamo N, Verma MJ, Mc Cluskey PJ, Lloyd A, Wakefield D. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res. 1996;15:1060-8.
  • 17. Küchle M, Nguyen N, Hannapel E. The blood-aqueous barrier in eyes with pseudoexfoliation syndrome. Ophthalmic Res. 1995;27:136-42.
  • 18. Sethi CS, Bailey TA, Luthert PJ, Chong NH. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol. 2000;84:654–66.
  • 19. Schumacher S, Schlötzer-Schrehardt U, Martus P, Lang W, Naumann GO. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet. 2001;357:359–60
  • 20. Kara S, Yıldırım N, Özer A, Çolak Ö, Şahin A. Matrix metalloproteinase-2, tissue inhibitör of matrix metalloproteinase-2, and transforming growth factor beta 1 in the aqueous humor and serum of patients with pseudoexfoliation syndrome. Clin Ophthalmol. 2014;8:305-9.
  • 21. Djordjević-Jocić J, Zlatanović G, Veselinović D, Jovanović P, Djordjević V, Zvezdanović L et al. Transforming growth factor beta1, matrix-metalloproteinase-2 and its tissue inhibitor in patients with pseudoexfoliation glaucoma/syndrome. Vojnosanit Pregl. 2012;69:231–6.

Pseudoexfoliation and level of matrix metalloproteinase-2 in the aqueous humor

Yıl 2019, Cilt: 44 Sayı: 3, 835 - 839, 30.09.2019
https://doi.org/10.17826/cumj.507221

Öz

Purpose: The aim of this study was to investigate the metalloproteinase-2 (MMP-2) levels in aqueous humor of patients with primary open-angle glaucoma (POAG), pseudoexfoliation syndrome (PES) and pseudoexfoliative glaucoma (PEG) .

Materials and Methods: In this prospective study, MMP-2 levels were measured by immunoassay ELISA method in humorous aqueous samples taken from 117 eyes of 97 patients with PES, PEG, PAAG cases and cataract cases in the control group (CG). Each group was compared with the control group and each other.

Results: The mean total MMP-2 levels detected in aqueous humor were 56.69 ± 51.3 ng / ml in the CG,  97.84 ± 81.12 ng / ml in the PES group, 108.00 ± 83.7 ng / ml in the PEG group and 83.89 ± 71.68 ng / ml in the POAG group. Despite the high levels of MMP-2 in the PES, PEG and POAG groups compared with the CG, there was no statistically significant difference for mean MMP-2 levels in aqueous humor between the PES, PEG and PAAG groups.

Conclusion: In our study it was found that the mean MMP-2 levels were higher in the PE groups than both CG and POAG group. However, there was no statistically significant difference between the PE group and the POAG group. It has been concluded that the distruption of the MMP-2 turnover may be one of the important mechanisms in PEM accumulation in cases with PE and plays an important role in the IOP increase.


Kaynakça

  • 1. Schlötzer-Schrehardt U, Naumann GOH. Morphology of exfoliation syndrome. In Exfoliation Syndrome and Exfoliative Glaucoma. ((Eds G Holló, AG Konstas):35-42. Savona, Italy, European Glaucoma Society, 2012.
  • 2. Schweitzer C. Pseudoexfoliation syndrome and pseudoexfoliation glaucoma. J Fr Ophthalmol. 2018;41:78-90.
  • 3. Gartaganis SP, Georgakopoulos CD, Mela EK. Matrix metalloproteinases and their inhibitors in exfoliation syndrome. Ophthalmic Res. 2002;34:165-71.
  • 4. Ritch R, Schöltzer-Schrehardt U. Exfoliation syndrome. Survey Ophthalmol. 2001;45:265-315.
  • 5. Garweg JG, Zandi S, Pfister IB, Skowronska M, Gerhardt C. Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma. PLoS One. 2017;12:e0182571.
  • 6. Grzybowski A, Kanclerz P, Ritch R. The history of exfoliation syndrome. Asia Pac J Ophthalmol (Phila). 2019;8:55-61.
  • 7. Clark AF. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci. 1998;39:2514–6.
  • 8. Van Buskirk EM, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol. 1992;113:447-52.
  • 9. Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117–25.
  • 10. Määttä M, Tervahartiala T, Harju M, Airaksinen J, Autio-Harmainen H, Sorsa T. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. J Glaucoma. 2005;14:64–9.
  • 11. Bradley JM, Vranka J, Colvis CM, Conger DM, Alexander JP, Fisk AS et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649–58.
  • 12. Ando H, Twining SS, Yue BY JT. MMPs and proteinase inhibitors in the human aqueous humor. Invest Ophthalmol Vis Sci. 1993;34:3541-8.
  • 13. Woessner JF Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci. 1994;732:11–21.
  • 14. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–4.
  • 15. Kee C, Son S, Ahn BH. The relationship between gelatinase A activity in aqueous humor and glaucoma. J Glaucoma 1999;8:51-5.
  • 16. Digirolamo N, Verma MJ, Mc Cluskey PJ, Lloyd A, Wakefield D. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res. 1996;15:1060-8.
  • 17. Küchle M, Nguyen N, Hannapel E. The blood-aqueous barrier in eyes with pseudoexfoliation syndrome. Ophthalmic Res. 1995;27:136-42.
  • 18. Sethi CS, Bailey TA, Luthert PJ, Chong NH. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol. 2000;84:654–66.
  • 19. Schumacher S, Schlötzer-Schrehardt U, Martus P, Lang W, Naumann GO. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet. 2001;357:359–60
  • 20. Kara S, Yıldırım N, Özer A, Çolak Ö, Şahin A. Matrix metalloproteinase-2, tissue inhibitör of matrix metalloproteinase-2, and transforming growth factor beta 1 in the aqueous humor and serum of patients with pseudoexfoliation syndrome. Clin Ophthalmol. 2014;8:305-9.
  • 21. Djordjević-Jocić J, Zlatanović G, Veselinović D, Jovanović P, Djordjević V, Zvezdanović L et al. Transforming growth factor beta1, matrix-metalloproteinase-2 and its tissue inhibitor in patients with pseudoexfoliation glaucoma/syndrome. Vojnosanit Pregl. 2012;69:231–6.
Toplam 21 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma
Yazarlar

Emine Çiloğlu 0000-0002-1266-3333

Neşe Doğan Bu kişi benim 0000-0001-8836-1588

Nusret Özdemir Bu kişi benim 0000-0002-6235-1960

Yayımlanma Tarihi 30 Eylül 2019
Kabul Tarihi 9 Ocak 2019
Yayımlandığı Sayı Yıl 2019 Cilt: 44 Sayı: 3

Kaynak Göster

MLA Çiloğlu, Emine vd. “Psödoeksfoliasyon Ve aköz hümörde Matriks Metalloproteinaz-2 düzeyi”. Cukurova Medical Journal, c. 44, sy. 3, 2019, ss. 835-9, doi:10.17826/cumj.507221.